FRANKFURT, May 4 (Reuters) – Bayer AG said on
Thursday its Regorafenib cancer treatment drug helped extend the
lives of liver cancer sufferers according to the results of a
Phase III clinical trial.
The post Bayer says its drug extends lives of liver cancer patients appeared first on NASDAQ.